-
This pharmaceutical company has another drug review! Since the second half of the year, a total of 3 varieties have been evaluated
Time of Update: 2023-01-05
According to the announcement, isoniazid tablets (specifications: 300mg, 100mg) of Mingxing Pharmaceutical, a wholly-owned subsidiary of the company, have passed the consistency evaluation of the quality and efficacy of generic drugs.
-
The 52-week data of the Phase 3 clinical trial of Longpei auxin China was first released
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];VISEN Pharmaceuticals, an innovative biopharmaceutical company focusing on endocrine-related therapeutics, announced for the first time on November 17 the main research data of its phase 3 pivotal clinical trial of long-acting growth hormone (weekly formulation), lonapegsomatropin.
-
The next city in the non-oncology field! Ascentage Pharma's EED inhibitor APG-5918 for the treatment of anemia indication IND was accepted by CDE
Time of Update: 2023-01-05
HK) announced on November 22 that the company's application for a new drug (IND) application for the treatment of anemia-related diseases by APG-5918, an innovative embryonic ectoderm development protein (EED) inhibitor, has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, which will open the exploration of non-oncology fields.
-
Transcenta announces two scientific posters at SITC 2022
Time of Update: 2023-01-05
Poster #771: A first-in-human, open-label, dose-escalation, and dose-extended Phase I study of TST005 in subjects with locally advanced or metastatic solid tumors TST005 is a novel bifunctional fusion protein that combines a high-affinity PD-L1 monoclonal antibody with TGF-β trap with enhanced stability in an IgG1 backbone silent by Fc. This study explores the safety, tolerability, and preliminary antitumor activity of TST005 in solid tumors.
-
The Race High campus is in full swing! Come and pick up your winter milk tea!
Time of Update: 2023-01-05
Hi! Hi! Hi! The "Sai High Campus" activity is in full swing, Universal Studios tickets, video website members, cultural and creative gift boxes. . . Three major activities good gifts non-stop High exp
-
CANbridge CAN106 for the treatment of myasthenia gravis is certified as an orphan drug
Time of Update: 2023-01-05
" " About CAN106 CAN106 is an innovative, long-acting recombinant humanized monoclonal antibody in clinical development that binds to and neutralizes C5, a complement system protein, thereby preventing the formation of membrane-attack complexes (MACs), which cause cell lysis (destruction) and other associated symptoms.
-
The atopic dermatitis treatment method "BRE-AD01" developed by Brexogen of South Korea using exosome platform technology was accepted for phase I clinical trials by the US FDA
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];The atopic dermatitis therapy "BRE-AD01" developed by Brexogen of South Korea using its own exosome platform technology was accepted by the US FDA for phase I clinical trials, and is the first atopic dermatitis therapy based on exosome platform technology to enter phase I clinical trials in major countries.
-
BeiGene will report the ALPINE trial at the American Society of Hematology (ASH) 2022 Annual Meeting on the ALPINE trial. Compare Yike? Achieving progression-free survival (PFS) efficacy outcomes for oral presentation of a summary of the latest breakthroughs
Time of Update: 2023-01-05
The company announced November 22 that it will present an oral summary of the latest breakthrough in the results of the end-of-life analysis of its ALPINE trial at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, USA.
-
BeiGene's BRUKINSA? Zebratinib is approved by the European Commission for the treatment of adults with chronic lymphocytic leukemia
Time of Update: 2023-01-05
The company announced on November 17 that the European Commission (EC) has approved BRUKINSA ® (zebrutinib) for the treatment of adults with treatment-naïve (TN) or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
-
Tianyan Pharmaceutical announced the clinical data of ADG116, an anti-CTLA-4 neotope anti-CTLA-4 epitope, at SITC 2022, demonstrating highly differentiated safety and anti-tumor activity for patients with refractory tumors treated with multiple lines
Time of Update: 2023-01-05
Tianyan Pharmaceuticals (the "Company" or "Tianyan ") (NASDAQ: ADAG) is a platform-driven, clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer immunoth
-
RedHill accelerates Opaganib nuclear radiation protection
Time of Update: 2023-01-05
Government Funded Opaganib Radiation Protection Study - Summary of Results: Efficacy of Opaganib on the lethality of TBI (total body irradiation) in C57BL/6 mice Excipients-treated mice developed severe gastrointestinal impairment and all animals had to be euthanized within 14 days of exposure.
-
TD Biologics announces the latest advances in the clinical trial of the first-of-its-kind HPK1 inhibitor, CFI-402411, at the 2022 STIC Annual Meeting
Time of Update: 2023-01-05
TD Biologics, a clinical-stage biotechnology company developing new cancer drugs, announced on November 11 that CFI-402411, the world's first oral inhibitor of hematopoietic progenitor cell kinase 1
-
Ascentage Pharma's EED inhibitor APG-5918 has been approved for Phase I clinical trial in China and will advance the clinical development of advanced solid tumors or hematologic malignancies
Time of Update: 2023-01-05
HK) announced on November 10 that APG-5918, a class 1 embryonic ectoderm development protein (EED) inhibitor under development, has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to carry out phase I clinical trials for the treatment of advanced solid tumors or hematologic malignancies.
-
Strictly abide by the rule of law defense line, Yangzijiang Pharmaceutical Group held the "clear system, abide by procedures, strict implementation" master
Time of Update: 2023-01-04
"This is the "Integrity and Compliance Guidelines" carefully compiled and issued by our Jiangsu Joint Stock Factory, which is our small family rule!" On November 20, in the center of the podium of the Yangtze River Academy, an employee was holding a red paper document to show to the audience.
-
Qilu Pharma announced the latest results of the Phase II study of QL1604 combined with chemotherapy for the first-line treatment of patients with advanced cervical cancer at ESMO Asia 2022
Time of Update: 2023-01-01
"Qilu Pharmaceutical is one of the large-scale comprehensive modern pharmaceutical enterprises, integrating R&D, production and sales of finished preparations and APIs. On December 4, 2022, at the 2022 Asian Congress of the European Society of Oncology (ESMO), Qilu Pharmaceutical announced the results of the phase II clinical study of QL1604 combined with chemotherapy in the first-line treatment of patients with relapsed or metastatic (R/M) cervical cancer in the form of an oral report (Proffered Paper, 179O).
-
Tyfil Biopharma announces the completion of the X0002 US Phase III clinical trial to recruit and enroll subjects
Time of Update: 2023-01-01
Taifeier Biomedical (Suzhou) Co. , Ltd. (hereinafter referred to as Taifeil) recently announced that its self-developed new molecular entity drug X0002 project in the United States Phase III clinical
-
BioVaxys announced successful trial production of disemiptenated vaccines
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];BioVaxys Technologies (CSE: BIOV) (FRA:5LB) (OTCQB:BVAXF) (hereinafter referred to as "BioVaxys" or the "Company") is pleased to announce that the Company's disemipten autologous ovarian cancer vaccine BVX-0918 has successfully completed sterilization and sterile pilot manufacturing.
-
Biocytogen successfully developed the fully human nanobody mouse RenNano
Time of Update: 2023-01-01
Compared with the few other nanobody models in the world, Biocytogen's RenNano® mice carry a complete human antibody heavy-chain variable region gene with in-situ position, and the fully human single-chain antibody sequence produced can be used for drug development without in vitro humanization modification, saving a lot of time and costs, and reducing the risk of subsequent development.
-
Dry! Bicken Prenol Drug Study Report
Time of Update: 2023-01-01
Clinical application The current global predomination of Bickenpreferol tablets is as a complete regimen for the treatment of adults with human immunodeficiency virus type 1 (HIV-1) infection and there is no current or previous evidence of viral resistance to integrase inhibitors, emtricitabine, or tenofovir.
-
Hengrui Pharmaceutical has ushered in good news in the field of diabetes drugs!
Time of Update: 2023-01-01
At the end of 2021, Hengrui Pharmaceutical's first Class 1 innovative drug in the field of diabetes was approved for marketing, which took 10 years of research and development and belongs to the innovative SGLT2 inhibitor.
